Botulinum toxin

Galderma announces progress with RelabotulinumtoxinA regulatory submissions

Retrieved on: 
Monday, October 2, 2023
FDA, Health, Other Health, Clinical Trials, General Health, Biotechnology, Partnership, International, Symantec Endpoint Protection, ICC, Botulinum toxin, Patient, International Chamber of Commerce, CRL, R, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Safety, Commerce, Pharmaceutical industry, Dietary supplement, Ipsen, Galderma, Chemistry

Galderma, the emerging pure-play dermatology category leader, announced today updates related to the regulatory progress of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA (QM-1114) to the U.S. Food and Drug Administration (“FDA”).

Key Points: 
  • Galderma, the emerging pure-play dermatology category leader, announced today updates related to the regulatory progress of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA (QM-1114) to the U.S. Food and Drug Administration (“FDA”).
  • On September 28, 2023, the International Chamber of Commerce (ICC) issued its award on the arbitration commenced by Galderma in 2021 regarding the regulatory filing strategy for RelabotulinumtoxinA, and as a result, the arbitration is complete.
  • Galderma remains responsible for development, regulatory filing and strategy, manufacturing, and commercialization.
  • Regulatory approval submissions and issued certificates will ultimately be in the name of Ipsen.

North America Aesthetic Injectable Procedures Count Analysis Report 2023: Botulinum Toxin Type A Procedures, Hyaluronic Acid Filler Procedures and Non-Hyaluronic Acid Filler Volumes 2015-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 27, 2023
Vitamins, Supplements, Other Health, Health, Cosmetics, Retail, Growth, Botulinum toxin, Silviculture

The "North America Aesthetic Injectable Procedures Count by Segments (Botulinum Toxin Type A Procedures, Hyaluronic Acid Filler Procedures and Non-Hyaluronic Acid Filler Procedures) and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Aesthetic Injectable Procedures Count by Segments (Botulinum Toxin Type A Procedures, Hyaluronic Acid Filler Procedures and Non-Hyaluronic Acid Filler Procedures) and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive databook report focuses on key aesthetic injectable procedures in North America, providing valuable insights into the market.
  • The report includes procedure volume data for Botulinum Toxin Type A Procedures, Hyaluronic Acid Filler Procedures, and Non-Hyaluronic Acid Filler Procedures, spanning from 2015 to 2030.
  • By understanding the trends and dynamics within these segments, companies can develop investment strategies that align with the expected strong growth in the near future, ensuring their success in the aesthetic injectable procedures market in North America.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Revance Therapeutics, Inc. - RVNC

Retrieved on: 
Monday, September 25, 2023
LLP, Prior, Botulinum toxin, Pomerantz, Therapy, News, Private investigator

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC).

Key Points: 
  • NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC).
  • The investigation concerns whether Revance and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

Retrieved on: 
Tuesday, August 29, 2023
AEON, Torticollis, Migraine, Week, Safety, Efficacy, Neck, Trial of the century, Bella Center Copenhagen, Patient, FDA, Botulinum toxin, NYSE, Pharmaceutical industry

The data was previously released by the Company in September 2022.

Key Points: 
  • The data was previously released by the Company in September 2022.
  • The poster titled, “A Phase 2, Double-blinded, Placebo-controlled Trial to Evaluate the Efficacy and Safety of ABP-450 (PrabotulinumtoxinA) in Adults With Isolated Cervical Dystonia,” was presented by Chad Oh, the Company’s Chief Medical Officer.
  • “We look forward to advancing the development of ABP-450 as a treatment option for patients living with this debilitating condition.
  • In addition, we are on track to announce the topline data from our ongoing Phase 2 study of ABP-450 in episodic migraine in fall of 2023.”

Sisram Medical Announces First-Half 2023 Financial Results

Retrieved on: 
Wednesday, August 23, 2023
Opus, Alma, IBSA, Clinical trial, LMNT, Botulinum toxin, Pakistan Software Export Board, Dentist, Beauty, Acquisition, Patient, Physician, National Medical Products Administration, United Kingdom, Growth, Yoy, The Company, FDA, Health, Clothing, Pharmaceutical industry, Video game, Fine chemical, Retail, Medical device, Tourism

HONG KONG, Aug. 23, 2023 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused branding, including energy-based devices, injectables, aesthetics and digital dentistry, personal care, and more, today announced its unaudited consolidated interim results for the six months ended June 30, 2023 (the "Reporting Period").

Key Points: 
  • After consolidation, revenue from the Chinese energy-based device market is expected to grow significantly in H2 2023.
  • On a global scale, China serves as the pioneering market for Sisram Medical within the wellness ecosystem.
  • Mr. Liu Yi, Chairman and Executive Director of Sisram, commented: "Following the first half of 2023, we've achieved significant milestones in strategic deployment.
  • Mr. Lior Dayan, CEO of Sisram and Alma, said: "The first half of 2023 was pivotal for Sisram, as we continue our transition from a product-centered approach to a customer-centric approach and present significant achievements in building our unique wellness ecosystem.

Esthetic Treatments Can Improve Your Perceived Personality

Retrieved on: 
Tuesday, August 15, 2023
Lifting, Botulinum toxin, Personality, Research, Chin, Anger, Social media, MD, Character, Face, Filler (linguistics), Mouth, Cosmetics

Esthetic treatments have been found to make a dramatic difference in how people are perceived.

Key Points: 
  • Esthetic treatments have been found to make a dramatic difference in how people are perceived.
  • Cynthia Elliott, MD, owner of the esthetic medical practice Skinspirations, highlights how nonsurgical cosmetic facial treatments can help people project the personality and look they desire.
  • (14)
    Luckily, research shows that cosmetic facial treatments can improve the first impression a person makes by both increasing attractiveness and changing perceived character traits.
  • "(15)
    Injectable esthetic treatments can make dramatic differences in the personality traits suggested by an individual's face.

Global Botulinum Toxin Market Analysis 2023: A $15.3 Billion market by 2030, Driven by Growing Demand for Aesthetic Procedures and Therapeutic Applications - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 8, 2023
Cosmetics, Retail, Migraine, COVID-19, Woman, Research, USD, Dermatology, Incidence, Botulinum toxin, Developed country, Lip, Growth, Ageing, Torticollis, Canning, Speciality chemicals

The "Botulinum Toxin Market Size, Share & Trends Analysis Report By Type (Botulinum Toxin Type A, Botulinum Toxin Type B), By End Use (Therapeutic, Aesthetic), By Region, And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Botulinum Toxin Market Size, Share & Trends Analysis Report By Type (Botulinum Toxin Type A, Botulinum Toxin Type B), By End Use (Therapeutic, Aesthetic), By Region, And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The increasing demand for minimally invasive or non-invasive procedures in aesthetics is expected to fuel the growth of the botulinum toxin market during the forecast period.
  • Additionally, the expanding use of botulinum toxin in therapeutic applications, along with growing research and development initiatives, is anticipated to drive further market expansion.
  • The COVID-19 pandemic has had a significant impact on the global botulinum toxin market.

Empower Aesthetics Announces Appointments to its Board of Directors

Retrieved on: 
Thursday, August 3, 2023
Retail, Luxury, Health, Practice Management, Other Health, General Health, SPAC, Barr, US Foods, Senior, American Capital, Marketing, Partner, Bangladesh Technical Education Board, Cal, Private duty nursing, Hospital, Acquisition, Collection, Botulinum toxin, Jewelry (group), DTC, Restaurant, University, Empower, Food, Macdonald, Uzo Asonye, Milken Institute, Growth, Textbook, Dermatology, Business, E-commerce, David G. Booth, Adviser, Rosewood Hotel Group, The Estée Lauder Companies, Stanford Graduate School of Business, Merrill (company), Therapy, Nursing, Aesthetics, Elective surgery, McGraw Hill Education, KKR, American City Business Journals, Practice, BSN, Human, Management, Dentistry, Sculptra, Operation

Empower Aesthetics (“Empower”), an Austin-based national medical aesthetics platform, today announced the appointment of three directors and seven independent directors to its board, including David Barr as Lead Director.

Key Points: 
  • Empower Aesthetics (“Empower”), an Austin-based national medical aesthetics platform, today announced the appointment of three directors and seven independent directors to its board, including David Barr as Lead Director.
  • He is also on the Board of Directors of Brightview, Shore Capital's medication-assisted addiction treatment platform investment.
  • “I am thrilled to serve alongside this Board of highly experienced directors and partner with the Empower leadership team to provide tools and expertise to help medical aesthetics brands achieve scale,” said Barr.
  • “We are privileged to have assembled such a world-class Board of Directors,” said Jeff Helfgott, CEO at Empower Aesthetics.

Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®

Retrieved on: 
Thursday, June 22, 2023
Luxury, Women, Clinical Trials, Biotechnology, Health, Cosmetics, Consumer, General Health, Retail, Botulinum toxin, Interim, Sale, Trial of the century, Congress, Development, Data, Patient, GLS, World Congress, Safety, Pharmaceutical industry, Research

Presentation of the full dataset will be planned for a medical meeting in Q4 2023.

Key Points: 
  • Presentation of the full dataset will be planned for a medical meeting in Q4 2023.
  • “Concluding this Phase 2 clinical study marks another significant milestone for Evolus and our commitment to delivering continued product innovation,” said Rui Avelar, M.D., Chief Medical Officer and Head of Research and Development, Evolus.
  • The study has three arms: Jeuveau Extra-Strength 40U and two active controls, BOTOX® 20U and Jeuveau 20U.
  • Through the company’s TRANSPARENCY Clinical Program, Jeuveau was clinically proven to temporarily improve moderate to severe glabellar lines or “11’s” in adults and included the largest head-to-head pivotal study versus BOTOX®.

Top L.A. Facial Plastic Surgeon, Dr. Jacob Sedgh, is One of the First Exclusive Providers to Offer the New FDA-Approved Daxxify™, an Alternative to Botox Treatment

Retrieved on: 
Thursday, June 1, 2023
Well, University, Rhinoplasty, WEST, University of Pittsburgh Medical Center, Cancer, Head, Research, Attention, Neck, TMJ, Otorhinolaryngology, Eyebrow, Nose, Suite, Patient, Longevity, Chin, FDA, Penn State Milton S. Hershey Medical Center, Medical device, Botulinum toxin, Sunset Boulevard

WEST HOLLYWOOD, Calif., June 1, 2023 /PRNewswire-PRWeb/ -- Dr. Jacob Sedgh is pleased to announce that DAXXIFY™, the only long-lasting, peptide-powered wrinkle injection treatment, is now available at his practice. Well-respected Los Angeles plastic surgeon Dr. Sedgh is one of just a few select providers to currently offer this innovative treatment to patients. Daxxify is a new injectable wrinkle treatment that's FDA-approved to improve the appearance of moderate to severe glabellar lines, frown lines or "elevens" between the eyebrows. It can be used off-label to treat other wrinkles, like forehead furrows, crow's feet and bunny lines, as well as platysmal bands in the neck and dimpling of the chin. As with other toxins, it can also be injected into the masseter muscles to soften a square, bulky jaw while reducing the clenching and grinding associated with TMJ. Like Botox, Dysport, and Xeomin, Daxxify (a.k.a. Daxi) works by temporarily blocking the release of the neurotransmitter that causes muscle movement. This smooths the "dynamic wrinkles" and prevents new expression lines from forming. What's unique about Daxxify is its longevity with clinical studies showing an improvement in frown lines for six to nine months (compared to the standard three to five-month result offered by previously approved neuromodulators, like Botox). Daxxify is safe and effective for most patients and is unique because it is the only formulation that uses a novel peptide as a stabilizer and does not contain human or animal byproducts. With 20 years of research behind it and the largest phase-3 clinical trial program done on frown line treatment, patients can feel confident that this treatment is safe on most skin types.

Key Points: 
  • WEST HOLLYWOOD, Calif., June 1, 2023 /PRNewswire-PRWeb/ -- Dr. Jacob Sedgh is pleased to announce that DAXXIFY™, the only long-lasting, peptide-powered wrinkle injection treatment, is now available at his practice.
  • Well-respected Los Angeles plastic surgeon Dr. Sedgh is one of just a few select providers to currently offer this innovative treatment to patients.
  • Daxxify is a new injectable wrinkle treatment that's FDA-approved to improve the appearance of moderate to severe glabellar lines, frown lines or "elevens" between the eyebrows.
  • Dr. Sedgh then completed a fellowship at Penn State Hershey Medical Center focusing on facial cosmetic and reconstructive surgery.